Product name

Summary

Organization name

Profile

Until 50 years ago, there were no medicines to cure TB. Now, strains that are resistant to a single drug have been documented; what is more, strains of TB resistant to all major anti-TB drugs have emerged. A particularly dangerous form of drug-resistant TB is multidrug-resistant TB (MDR-TB), which is defined as the disease caused by TB bacilli resistant to at least isoniazid and rifampicin, the two most powerful anti-TB drugs. Rates of MDR-TB are high in some countries, especially in the former Soviet Union.

Technology

All of the following substances are showing strong antibacterial effects against gram-positive bacteria, especially against mycobacteria.

TO 10-00006: New O-(aminoalkyle)-derivatives based on monosaccharides

This invention discloses new O-(aminoalkyle)-derivatives from monosaccharides, a method for its production, as well as their application as antibiotics. The monosaccharide scaffold allows these new substances siderophore-like functions. In addition to the anti-mycobacterial an anti-fungal effect is proven. These substances could be used for the development of a new class of antibiotics.

German patent application is pending.

TO 10-00026: New thiazinone derivatives  

This invention discloses new thiazin derivatives and their use as antibacterial agents against infectious diseases of mammals (humans and animals) caused by mycobacteria, including diseases like leprosy. In particular the thiazin derivatives show strong antibacterial activity even against multidrug-resistant Mycobacterium tuberculosis strains.

PCT application is pending.

TO 10-00036: Drugs containing certain substances of dinitrobenzene

The technology relates to dinitrobenzol derivatives for the treatment of tuberculosis and malaria. The compounds have been analysed in cellular assays, and first validation studies in animal models have been performed.

German patent was granted.

TO 10-00042: Lydiamycins

This invention encloses new selectively active substances for the treatment of diseases caused by mycobacteria, a method for its production, as well as its application. These substances isolated from Streptomyces lydicus are called lydiamycins A - D and belong to the class of cyclodepsipeptides Lydiamycins are showing strong antibacterial properties without cytotoxic effects. Due to this lydiamycins are interesting drug candidates for the therapy of tuberculosis and also for leprosy.

German patent was granted. 

Commercial Opportunity

New alternative antibiotics like those mentioned above are urgently needed to combat tuberculosis especially caused by an increasing number of multiresistant pathogens and to cope with the re-increasing number of tuberculosis infections worldwide.

Advantages of the offered novel compounds are

• new lead structures for derivatisation
• patent protection extendable due to future optimized derivatives
• proven anti-mycobacterial activity, partially even against multidrugresistant Mycobacterium tuberculosis strains
• low cytotoxicity already shown for most of the drug candidates
• easy and cost effective biotechnological production by fermentation

A cooperation agreement with option for an exclusive or non-exclusive license or a license agreement (exclusive or non-exclusive) are possible deals.

Contact

Dr. Sabina Heim

heim(at)ascenion.de

About Ascenion

Ascenion is the exclusive partner of 12 life-science institutes in the Helmholtz and Leibniz Associations and of one Medical School, and coordinates technology transfer for the German National Genome Research Network. They currently market around 600 technologies, together with a varied range of research materials, e.g. antibodies, animal models and vectors.

Description File

Your feedback

back